Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cells for subacute intracerebral hemorrhage
ChiCTR2500095990Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human umbilical cord mesenchymal stem cells in intracerebral hemorrhage (ICH) (8 arms), sponsored by Tongji Hospital. Primary endpoints: Barthel Index scale score at month 12, Modified Rankin Scale score at month 12 and 4 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2500095990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095990.